Table 3.
MEK inhibitors
| Compound | Tumor | Primary Target(s) | Potential side effects |
|---|---|---|---|
| CI-1040 (Pfizer Inc.) | Breast cancer, Lung cancer, Pancreatic cancer, Colorectal cancer, Breast Neoplasm, Non small cell lung cancer, Pancreatic Cancers | MEK | Diarrhea, Asthenia, Rush, Nausea, Vomiting |
| PD-0325901 (Pfizer Inc.) | Carcinoma, Non small cell lung cancer, Melanoma, Breast cancer | MEK | Diarrhea, Nausea, Fatigue, Rash, Reversible visual disturbances, Vomiting |
| ARRY-438162 (Array BioPharma) | Metastatic Biliary Cancer, and Metastatic Colorectal Cancer | MEK | Recruiting Phase |
| AZD6244 (AstraZeneca) | Breast cancer, Colon cancer, Lung cancer, Kidney cancer, Metastatic colorectal cancer, Advanced/metastatic Melanoma, Pancreatic cancer, Non small cell lung cancer, Hepatocellular carcinoma | MEK | Papulopustular rash, Xerosis, Fissures, Pruritus, Telangiectasias, Hyperpigmentation, Dermatitis, Alopecia, Angular chelitis, Paronychea, Fatigue |
| RDEA119/BAY 86-9766 (Bayer/Ardea Biosciences) | Advanced cancer, cancer, Thyroid cancer Pancreatic | MEK | Low toxicity, further studies are needed |
| GSK1120212 (GlaxoSmithKline) | Solid tumors, Melanoma, Non small cell lung cancer, Pancreatic cancer | MEK, C-Raf, B-Raf, V600E, BRAF wt | Fatigue, Diarrhea |
| TAK-733 (Millennium Pharmaceuticals) | Advanced Non-hematologic malignancies, Metastatic melanoma | MEK | Recruiting |
| GDC-0973/XL581 (Genentech/Exelixis) | Metastatic Melanoma, Solid cancers | MEK | High toxicity, Diarrhea, Fatigue, Rash, Nausea, Vomiting |
| AZD8330/ARRY-424704 (AstraZeneca) | Advanced malignancies | MEK | Ongoing trial |
| RO5126766 (Hoffmann-La Roche) | Metastatic or advanced solid tumors | MEK | Recruiting |
| RO4987655 (Hoffmann-La Roche) | Advanced and/or metastatic solid tumors | MEK | Recruiting |
| RO5068760 (Hoffmann-La Roche) | Melanoma, Colorectal cancer | MEK | Preclinical Phase Studies |
| AS703026 (EMD Serono) | Acute Myeloid Leukemia, and Hematological Malignancies | MEK | Recruiting |